Neumirna Therapeutics
RNA Therapeutics Neurological Epilepsy Pain ASO Antisense Oligonucleotides mirna.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | €20.0m | Series A | |
| Total Funding | 000k | ||
| DKK | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Neumirna Therapeutics, a Danish biotechnology firm established in 2020, is focused on creating RNA-based therapies for neurological diseases. The company was founded by Dr. Henrik Klitgaard, Professor Sakari Kauppinen, and Lars Hellerung Christiansen. Dr. Klitgaard is a neuroscientist known for his work in epilepsy research and drug development, including leading the team that discovered the mechanism for two significant antiepileptic drugs. Professor Kauppinen is an expert in RNA-targeted therapeutics and previously supervised the discovery of the first miRNA-targeted drug to enter Phase 2 clinical trials. This collective expertise forms the foundation of Neumirna's approach.
The company's core business revolves around its proprietary drug discovery platform, which develops RNA therapies targeting microRNAs (miRNAs) to address the root causes of neurological conditions. This strategy aims to provide disease-modifying drugs, a departure from treatments that only manage symptoms. Neumirna's primary markets are patients with intractable conditions, specifically drug-resistant epilepsy (DRE) and Parkinson's disease (PD). The company's business model is centered on the research, development, and eventual commercialization of these novel therapeutics. Its revenue generation will depend on the successful clinical development and approval of its drug candidates.
Neumirna's lead product candidate is NMT.001, an Antisense Oligonucleotide (ASO) therapy designed for patients with DRE, a condition that affects millions who are not well-served by current options. Preclinical studies of NMT.001 have demonstrated significant efficacy in animal models. The company is leveraging a recent €20 million Series A financing to advance NMT.001 into clinical trials and to scale its research and development platform for other neurological disorders. This funding was co-led by Angelini Ventures and Invivo Partners, with continued support from seed investors. The company has also received support from entities like the Michael J Fox Foundation and the Innovation Fund Denmark.
Keywords: RNA therapeutics, neurological disorders, microRNA, drug-resistant epilepsy, Parkinson's disease, antisense oligonucleotide, biotech, neuropharmacology, clinical trials, drug discovery